[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100540810":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":30,"responsibleParty":46,"collaborators":10,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":50,"sex":56,"minAge":57,"maxAge":10,"enrollmentInfo":58,"targetDuration":10,"studyType":61,"phases":10,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"European Institute of Oncology","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"WB-MRI",null,"Each patient will undergo imaging with CT, BS and WB-MRI at each study timepoint",[13],"Procedure: Imaging evaluation",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"PROCEDURE","Imaging evaluation","each patient will undergo imaging with CT, BS and WB-MRI at each study timepoint",[9],[21],{"name":22,"affiliation":5,"role":23},"Giuseppe Petralia","PRINCIPAL_INVESTIGATOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Giuseppe Petralia, MD","CONTACT","+39 02 9437 2901","giuseppe.petralia@ieo.it",[31],{"facility":32,"status":33,"city":34,"state":10,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"IEO Istituto Europeo di Oncologia","RECRUITING","Milan","20141","Italy","IT",{"type":39,"coordinates":40},"Point",[41,42],9.18951,45.46427,{"lat":42,"lon":41},[45],{"name":22,"role":27,"phone":10,"phoneExt":10,"email":29},{"type":47,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100540810","response-evaluation-of-cancer-therapeutics-in-metastatic-castration-resistant-prostate-cancer-to-the-bone-100540810",false,"NCT06321679","Response Evaluation of Cancer Therapeutics in Metastatic Castration-Resistant Prostate Cancer to the Bone","Response Evaluation of Cancer Therapeutics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) to the Bone: A Whole Body MRI Study","RESPECT","Inclusion Criteria:\n\n* Histological diagnosis of castration-resistant prostate cancer,\n* Single or multiple bone metastases,\n* Life expectancy of over 6 months,\n* No current active malignancy other than prostate cancer,\n* Provision of written informed consent.\n\nExclusion Criteria:\n\n* Absolute contraindication to WB-MRI, CT or BS,\n* Radical treatment of sole site of metastatic disease (e.g. Cyberknife to solitary metastatic lesion),\n* Psychological, familial, sociological or geographical conditions that would hamper compliance with the study protocol; such conditions are to be discussed with the patient as part of the informed consent process.","MALE","18 Years",{"count":59,"type":60},40,"ESTIMATED","OBSERVATIONAL","This study is aimed to compare whole body MRI (WB-MRI) with Bone Scintigraphy (BS) and Computerized Tomography (CT) scans in patients receiving treatment for metastatic castration-resistant prostate cancer to the bone.\n\nThis is a monocentric, prospective observational study.",[64],"Castration-resistant Prostate Cancer",[66,67],"castration-resistant prostate cancer","whole body magnetic resonance imaging","2024-03-13",{"date":70,"type":71},"2024-03-20","ACTUAL",{"date":73,"type":71},"2020-07-03",{"date":75,"type":60},"2027-12-31",{"name":5,"class":6},1]